Core Insights - The company Shiyao Group (01093) has received FDA approval for its self-developed chemical Class 1 new drug SYH2070 injection, a double-stranded small interfering RNA (siRNA) drug, allowing clinical trials in the United States [1] - The product has also been approved by the National Medical Products Administration of China to conduct clinical trials in China starting September 2025 [1] Product Details - SYH2070 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc), administered subcutaneously to target angiopoietin-like protein 3 (ANGPTL3), effectively lowering ANGPTL3 levels [1] - The drug aims to provide a long-lasting gene silencing effect, potentially serving as an ultra-long-acting siRNA drug for treating hypertriglyceridemia or mixed hyperlipidemia, with the ability to reduce the risk of elevated residual cholesterol levels [1] Clinical Research Findings - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and efficacy duration compared to similar siRNA products, showcasing prolonged drug effects, good safety profiles, and high patient compliance, highlighting its significant clinical development value [1]

Core Viewpoint - The company has received FDA approval for its self-developed chemical Class 1 new drug SYH2070 injection, a double-stranded small interfering RNA (siRNA) drug, allowing it to conduct clinical trials in the United States [1] Group 1 - The drug SYH2070 injection has also been approved by the National Medical Products Administration (NMPA) of China to conduct clinical trials starting from September 2025 [1]

Core Viewpoint - The approval of SYH2070 injection by the FDA marks a significant milestone for the company, enabling clinical trials in the U.S. and highlighting the potential of the drug in treating hypertriglyceridemia and mixed dyslipidemia [1] Group 1: Product Development - The SYH2070 injection is a first-class new chemical drug developed by the company, utilizing double-stranded small interfering RNA (siRNA) technology [1] - The drug targets ANGPTL3 to effectively lower its levels, which is crucial for managing triglyceride levels [1] - The product has also received approval from the National Medical Products Administration (NMPA) in China for clinical trials, expected to commence in September 2025 [1] Group 2: Mechanism and Efficacy - SYH2070 employs GalNAc for liver-targeted delivery, allowing for subcutaneous administration [1] - The drug demonstrates superior drug activity and prolonged efficacy compared to similar siRNA products, indicating a longer-lasting gene silencing effect [1] - Clinical pre-research shows that SYH2070 has differentiated advantages in terms of safety, patient compliance, and sustained drug action [1] Group 3: Market Potential - The drug is positioned to potentially reduce the risk of elevated residual cholesterol levels, making it a valuable candidate for clinical development in the relevant therapeutic areas [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its self-developed chemical new drug SYH2070 injection, a dual-strand siRNA drug, allowing it to conduct clinical trials in the United States. The drug is also set to receive approval from China's National Medical Products Administration for clinical trials by September 2025 [1]. Group 1: Product Details - SYH2070 is designed for liver-targeted delivery using GalNAc conjugation, administered subcutaneously to target ANGPTL3, effectively lowering its levels [1]. - The drug employs optimized sequences and chemical modifications to achieve prolonged gene silencing effects, positioning it as a long-acting siRNA drug for treating hypertriglyceridemia or mixed dyslipidemia, with potential to reduce the risk of elevated residual cholesterol levels [1]. Group 2: Clinical Research Insights - Preclinical studies indicate that SYH2070 outperforms similar siRNA products in terms of drug activity and efficacy duration, showcasing advantages such as sustained drug effects, good safety profile, and high patient compliance, highlighting its significant clinical development value [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈 ， 本 集 團 自 主 研 發 的 化 學 1 類 新 藥 SYH2070 注 射 液（ 雙 鏈 小 干 擾 RNA（「 si RNA 」）藥 物 ） （「該產 品」）已獲 得美 國食 品藥 品監 督管 理局 (FDA) 批 准， 可在 美國 開展 臨床 試驗 。該 產品 亦於2025年9月獲得中華人民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該產品是一款通過偶聯乙醯半乳糖胺(Gal NAc)實現肝臟靶向遞送的si RNA 藥物，以皮下給 藥的方式靶向血管生成素樣蛋白3（「ANGPTL3」），能有效降低ANGPTL3水平。通過優化序 列和化學修飾的策略，該產品實現更持久的基因沉默效果，有望成為超長效降低ANGPTL3 的si RNA藥物，適用 ...

Core Viewpoint - The domestic innovative drug industry is transitioning from a follower to FIC/BIC innovation, supported by engineer dividends, abundant clinical resources, and favorable policies, indicating a qualitative improvement as it enters the 2.0 era [1][2] Group 1: Industry Development - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies as they commercialize domestic products [2] - The upcoming ESMO conference in mid-October is anticipated to provide new investment opportunities through the release of relevant clinical data and business development (BD) activities [2] Group 2: Investment Climate - The investment landscape has improved since early this year, with a notable reversal in the financing trend for the innovative drug industry, particularly in the A/H market [3] - The recovery of IPO projects and financing activities in the secondary market is expected to positively impact investment data in Q3, benefiting domestic CROs and upstream research sectors [3] Group 3: Policy Support - Continuous advancement of commercial medical insurance policies since 2025 is likely to accelerate payment system reforms, easing supply-demand conflicts and supporting domestic innovation [4] - Fiscal policy enhancements are expected to increase market interest in domestic medical equipment stocks [4] Group 4: Target Companies - A-share targets include: BeiGene (688235.SH), Hengrui Medicine (600276.SH), Kelun Pharmaceutical (002422.SZ), WuXi AppTec (603259.SH), Tigermed (300347.SZ), New Industry (300832.SZ), BGI Genomics (688114.SH), Huatai Medical (688617.SH), and Dian Diagnostics (300244.SZ) [5] - H-share targets include: Kelun Biotech (06990), CSPC Pharmaceutical (01093), China Biologic Products (01177), CanSino Biologics (09926), WuXi Biologics (02269), Junshi Biosciences (01877), and Zai Lab (09688) [5]

Investment Rating - The report maintains an "Overweight" rating for the industry [3] Core Viewpoints - The report continues to recommend innovative pharmaceuticals and medical devices along the industry chain [2][7] - The performance of the pharmaceutical sector in September 2025 was weaker than the broader market, with the SW Pharmaceutical Biotech index declining by 1.7% compared to a 0.6% increase in the Shanghai Composite Index [16][22] - The report highlights that the medical service sub-sector performed relatively well, increasing by 1.8%, while medical devices and chemical preparations saw slight declines [22] Summary by Sections - **Investment Recommendations**: The report includes a list of A-share stocks with an "Overweight" rating, including Heng Rui Pharmaceutical, Kelun Pharmaceutical, East China Pharmaceutical, Changchun High-tech, Enhua Pharmaceutical, WuXi AppTec, Tigermed, Lepu Medical, United Imaging Healthcare, and Huatai Medical [7][9] - **Performance Analysis**: The report notes that the monthly portfolio of Guotai Junan Pharmaceuticals outperformed the pharmaceutical index in September 2025, with an average increase of 1.1% compared to a 0.7% increase in the overall pharmaceutical index [12][13] - **Market Comparison**: The report indicates that the pharmaceutical sector's premium level relative to all A-shares is currently at a normal level, with a relative premium rate of 77.5% as of the end of September 2025 [26][28]

每经AI快讯，10月9日，港股石药集团股价表现疲弱，跌幅扩大至4.99%，现价报9.33港元，总市值 1075.04亿港元。今年以来，公司股价累计上涨97.71%。 ...

Core Insights - China-based companies are responsible for 20% of drugs in development globally, highlighting the country's significant role in the pharmaceutical industry [1][6] - Regulatory and policy reforms in China have rapidly advanced its drug development landscape, with the country accounting for nearly double the percentage of drugs being developed compared to the 5EU, which is 11% [2][3] - The US remains the leader in drug development, holding a 40% share [2] Regulatory Initiatives - The Chinese government has implemented various regulatory initiatives over the last decade to enhance competitiveness, including the 2015 policy aimed at accelerating growth in the pharmaceutical and medtech sectors [3][4] - Modernization of clinical trials is a key focus, contributing to China's goal of becoming a dominant region for drug pipelines [3] Licensing and Transactions - There has been a significant increase in licensing deals between Chinese biotechs and Western pharmaceutical companies, with a notable $5.2 billion deal between AstraZeneca and CSPC Pharmaceuticals [4][5] - The NewCo deal structure has gained popularity, allowing rights to be assigned to a new company where companies and investors hold equity [5] - Licensing deals between US and Chinese biopharma companies reached record highs last year, showing a 280% increase from 2020 [5] Market Trends - Transactions across big pharma rose by 66%, increasing from $16.6 billion in 2023 to $41.5 billion in 2024, indicating China's status as a key location for discovering pipeline candidates [6] - China is transitioning from a "me-too" market to a global innovator, reshaping the global drug development landscape [6]

Core Viewpoint - The National Healthcare Security Administration has announced the 11th batch of centralized drug procurement, which will take place on October 21, covering 55 varieties and 162 specifications, including key areas such as antiviral and kidney disease treatment drugs [1][2]. Group 1: Drug Procurement Policy - The 11th batch of centralized procurement aims to stabilize clinical practices, ensure quality, prevent collusion, and avoid excessive competition [1]. - The new procurement rules will optimize price control mechanisms to prevent companies from underbidding, which previously led to unsustainable low prices [1][4]. - The focus on high-value consumables and medical devices is expected to benefit companies with strong cost advantages and product quality, particularly in major categories like cardiovascular and anti-infection drugs [4][5]. Group 2: Market Opportunities and Challenges - The centralized procurement policy presents both opportunities and challenges for pharmaceutical companies, prompting some generic drug firms to shift towards a combination of generics and innovation [2][5]. - The "anti-involution" trend in the procurement sector is expected to primarily benefit high-value consumables, which have been adversely affected by previous procurement rounds [2][4]. Group 3: Long-term Investment Perspective - Investors are advised to adopt a long-term perspective, as some innovative drug stocks are currently overvalued following previous market enthusiasm [3][9]. - The ongoing improvement of procurement policies is seen as a catalyst for the healthy development of the pharmaceutical industry, favoring large innovative drug companies with strong R&D capabilities [5][9]. Group 4: Company Performance and Projections - Companies like Kelun Pharmaceutical, Jingxin Pharmaceutical, and Fosun Pharma are highlighted for their strong R&D pipelines and potential for growth, with Kelun having over 30 projects focused on oncology [6][7]. - Fosun Pharma has made significant progress in its innovative transformation, with multiple products showing promising clinical trial results [6][8]. - China National Pharmaceutical Group is expected to have nearly 20 innovative products approved in the next three years, with several projected to exceed sales of 2 billion RMB [8].